
|Articles|March 15, 2003
Clinical drug trials may be key to reducing macular edema
Baltimore-Macular edema is the final common pathway for visual loss in many diseases, but so far, available treatments have not been effective in improving visual acuity to 20/20 in a significant percentage of patients, according to Julia A. Haller, MD, who spoke during the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine, here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
2
Pickleball, fireworks, eyecare in space, and IRIS registry data among lead stories from day 1 of AAO 2025
3
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
4
Ophthalmic innovation by the decades: The 2010s
5